# Cyclophosphamide

## Endoxan Asta inj 200mg

| TAH Drug Code      | [**IEND**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IEND)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of acute lymphoblastic leukemia (ALL), acute myelocytic leukemia (AML), breast cancer, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), Hodgkin lymphoma, mycosis fungoides, multiple myeloma, neuroblastoma, non-Hodgkin lymphomas (including Burkitt lymphoma), ovarian adenocarcinoma, retinoblastoma, and nephrotic syndrome.                                                                                                                                                                                                        |
| Dosing             | The dosage must be adapted to each patient individually.Unless otherwise prescribed the following dosages are recommended: - for continuous treatment in adults and children: 3-6 mg/kg body weight daily (= 120-240 mg/m2 body surface) - for intermittent treatment: 10-15 mg/kg body weight (= 400-600 mg/m2 body surface) at intervals of 2-5 days - for high-dose intermittent treatment, e.g. 20-40 mg/kg body weight (= 800-1600 mg/m2 body surface) and higher doses (e.g. for conditioning prior to bone-marrow transplantation) at intervals of 21-28 days. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to cyclophosphamide or its metabolites, urinary outflow obstructions, severe myelosuppression, severe renal or hepatic impairment, active infection (especially varicella zoster), severe immunosuppression.                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | GI upsets; alopecia; reticulo-endothelial system depression; hematuria; reversible amenorrhea & azoospermia; myocardial damage with very high doses; pigmentation, macrocytosis, water retention; induction of hyperglycemia or hypoglycemia; risk of secondary malignancies.                                                                                                                                                                                                                                                                                         |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

## Endoxan 50mg

| TAH Drug Code      | [**OEND**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OEND)                                                                                                                                                                                                                                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of acute lymphoblastic leukemia (ALL), acute myelocytic leukemia (AML), breast cancer, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), Hodgkin lymphoma, mycosis fungoides, multiple myeloma, neuroblastoma, non-Hodgkin lymphomas (including Burkitt lymphoma), ovarian adenocarcinoma, retinoblastoma, and nephrotic syndrome. |
| Dosing             | For continuous therapy 1-4 tablets (50-200 mg) daily; if necessary, more tablets may be taken. The dose recommendations given mainly apply to the treatment with cyclophosphamide as a monotherapy. In combination with other cytostatics of similar toxicity, a dose reduction or extension of the therapy-free intervals may be necessary.                   |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Hypersensitivity to cyclophosphamide or its metabolites, urinary outflow obstructions, severe myelosuppression, severe renal or hepatic impairment, active infection (especially varicella zoster), severe immunosuppression.                                                                                                                                  |
| Adverse Effects    | Nausea, vomiting; bone marrow depression, leukopenia; alopecia; mucosal ulceration; pigmentation; interstitial pulmonary fibrosis; fluid retention                                                                                                                                                                                                             |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                                |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                |

